Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Neutrophil Extracellular Traps & Their Role in Autoimmunity

Kathy Holliman  |  Issue: May 2018  |  May 18, 2018

A neutrophil in a blood smear.

A neutrophil in a blood smear.
Jarun Ontakrai / shutterstock.com

Certain medications have been associated for decades with the development of drug-induced autoimmunity. New research published in March 2018 in Arthritis & Rheumatology suggests that NETs (neutro­phil extracellular traps) are potentially implicated in the mechanisms that lead to drug-induced autoimmunity.1

Peter Grayson, MD, MSc, head of the Vasculitis Translational Research Program at the National Institute of Arthritis and Musculoskeletal and Skin Diseases, says that research related to NETs may have no current clinical implications, but he predicts that research focused on NETs “is likely to unlock novel therapeutic strategies in a range of rheumatologic diseases.” Understanding the role of NETs in drug-induced autoimmunity may be the next step toward clarifying the mechanisms of autoimmunity.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

NET formation is involved in the neutro­phil cell death process, called NETosis, which is different morphologically from other types of cell death, including apoptosis and necrosis. In NETosis, the dying neutrophils “can unwind their DNA and launch it out of the cell like a spiderweb to engulf and facilitate the elimination of pathogens,” Dr. Grayson explains. The process, however, can become aberrant in many rheumatologic diseases with the dysregulation of NET formation.

“What is surprising and potentially interesting for rheumatologists to understand is that there is only a small number of proteins inside these NETs, and many of them are the antigenic targets of autoantibodies in rheumatologic diseases,” Dr. Grayson says. Patients with rheumatoid arthritis make anticyclic citrullinated peptide (CCP) antibodies directed to proteins found in the NETs. Patients with lupus make antibodies to NET components. Proteinase 3 and myeloperoxidase, the antigenic targets of antineutrophil cytoplasmic antibodies (ANCA) are commonly found within NETs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“These proteins that are normally hidden inside a neutrophil get exposed to the adaptive immune system in a way that is immunogenic, which then can potentially lead to development of antibodies to those proteins,” says Dr. Grayson.

NET formation and impaired NET degradation have been implicated in the pathogenesis of both systemic lupus erythe­matosus (SLE) and ANCA-associated vasculitis (AAV). “The process of NETosis may contribute to causal mechanisms of disease in rheumatoid arthritis, lupus and AAV,” he says.

In NETosis, the dying neutrophils ‘can unwind their DNA & launch it out of the cell like a spiderweb to engulf & facilitate the elimination of pathogens,’ Dr. Grayson explains.

Triggering NET Formation, Degradation

Previous research that examined drug-induced autoimmunity looked at the effect of medications on lymphocytes. This new research by Dr. Grayson and colleagues looked at their effect on neutrophils and NETs. Medications associated with drug-induced autoimmunity can lead to development of a rheumatologic disease that “has a specific look or feel to it. It looks a lot like lupus mixed with ANCA vasculitis. We thought that because NETs are important in lupus and ANCA vasculitis, maybe the drugs are inducing NETs, since it’s a common theme to those conditions,” Dr. Grayson explains.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsDrug Updates Tagged with:neutrophil extracellular traps

Related Articles

    Rheumatology Researchers Explore Role of Neutrophils in Autoimmunity

    January 19, 2016

    SAN FRANCISCO—To unravel the mysteries of how autoimmunity begins in the body and, one day, to interrupt that process, rheumatology researchers are exploring the role of neutrophils, especially when they form and release neutrophil extracellular traps (NETs). At a panel discussion on Nov. 6, 2015, held at the American College of Rheumatology’s Basic Research Conference,…

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    February 16, 2021

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

    Rheum After 5: Introducing Dr. Grayson & the Affordable Rock ‘n’ Roll Act

    January 19, 2021

    Peter Grayson, MD, MSc, a tenure track investigator at the National Institutes of Health (NIH) Intramural Research Program, Bethesda, Md., sometimes wonders how his life would have turned out if the band he was playing in during college had signed a recording contract with a major record label. Dr. Grayson has been playing the piano…

    The Granulomatosis of Wegener’s

    May 16, 2011

    Delving deeper into the nonvasculitis aspects of the disease

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences